Edwards Lifesciences Corporation’s share price was $76.05 on September 15th. The company saw 11% revenue growth in Q2, beating expectations, with adjusted EPS at $0.67. Key catalysts ahead include broader TAVR adoption and U.S. approval of Sapien M3 in 2026. Management raised 2025 revenue guidance to 9–10%.

The stock climbed 5% post-Q2 results and is up 16% from January lows. Edwards Lifesciences remains undervalued despite recent gains, offering a five-year CAGR of 12.6%. The company leads in heart valve therapies, with Sapien as the only TAVR platform approved for asymptomatic patients in the U.S. and Europe.

A bullish thesis on Edwards Lifesciences Corporation highlighted its leadership in heart valve therapies, TAVR dominance, and expansion into mitral and tricuspid markets. The stock has appreciated approximately 3.86% since the thesis was covered in January 2025. The thesis is still relevant with renewed growth momentum and raised guidance.

Read more at Yahoo Finance: Edwards Lifesciences Corporation (EW): A Bull Case Theory